Search

Displaying results 3991 - 4000 of 10000 in total
  1. Drug

    ZYC300

    go.drugbank.com/drugs/DB04986
    Investigational

    It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells. … ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles.

  2. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15507
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  3. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16726
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  4. Drug

    Alacepril

    go.drugbank.com/drugs/DB21364
    Experimental

    The usage of the INN stem '-pril' in the name indicates that Alacepril is a angiotensin-converting enzyme inhibitor. Alacepril has a monoisotopic molecular weight of 406.16 Da.

    Categories: Agents Acting on the Renin-Angiotensin System
  5. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    A256758] Unlike BTK covalent inhibitors, such as [ibrutinib], that bind to the cysteine 481 (Cys481) amino acid within the active site of BTK, the inhibitory activity of pirtobrutinib is maintained even in … [L44863,L44873] In December 2025, pirtobrutinib received traditional FDA approval for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously

  6. Drug

    Flortaucipir

    go.drugbank.com/drugs/DB15033
    Investigational

    Flortaucipir is under investigation in clinical trial NCT03507257 (Longitudinal Early-onset Alzheimer's Disease Study Protocol).

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Bevacizumab zirconium Zr-89

    go.drugbank.com/drugs/DB14907
    Investigational

    Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Zinc dibutyldithiocarbamate

    go.drugbank.com/drugs/DB14194
    Approved

    Zinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.

  9. Drug

    TG-100801

    go.drugbank.com/drugs/DB05075
    Investigational

    TG100801 is a topically applied kinase inhibitor in macular degeneration patients. … It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological

  10. Drug

    Evogliptin

    go.drugbank.com/drugs/DB12625
    Investigational

    Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.

    Categories: Drugs Used in Diabetes